USITC to investigate Novartis patent complaint against Regeneron
The US International Trade Commission (USITC) will investigate Regeneron Pharmaceuticals for the alleged infringement of a patent owned by its rival Novartis, it announced in a notice posted yesterday, July 21.
The investigation is based on a complaint filed by Swiss multinational pharmaceutical company Novartis Pharma AG, and its US subsidiaries Novartis Pharmaceuticals Corporation and Novartis Technology, on June 19. Novartis filed a supplementary letter with the commission on July 10.
Novartis alleges that Regeneron infringed its ’631 patent and violated section 337 of the Tariff Act of 1930 by importing into the US and selling “certain pre-filled syringes for intravitreal injection” or “syringes that are pre-filled with ophthalmic medication, and components of such syringes, including barrels, plungers, and stoppers”. The company has requested that the USITC issue Regeneron with “a limited exclusion order” along with a “cease and desist” order.
The USITC’s chief administrative law judge will assign the case to one of the USITC’s administrative law judges (ALJ), who will schedule and hold a hearing. The ALJ will decide whether there has been a violation of section 337, to be reviewed by the commission.
The USITC sets a target date for the completion of an investigation within 45 days of its announcement. USITC remedial orders in section 337 cases become final 60 days after being issued, unless they are disapproved for policy reasons by Robert Lighthize, the US Trade Representative, within that period.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk